Acadian Asset Management
HRTX icon

Acadian Asset Management’s Heron Therapeutics HRTX Stock Holding History

Acadian Asset Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$65K Sell
153,011
-360,157
-70% -$289K ﹤0.01% 1828
2026
Q1 		$409K Buy
+513,168
New +$595K ﹤0.01% 1413
2024
Q4 		– Sell
-7,601
Closed -$15K – 1864
2024
Q3 		$15K Sell
7,601
-28,861
-79% -$68.9K ﹤0.01% 2010
2024
Q2 		$127K Buy
+36,462
New +$112K ﹤0.01% 1502
2024
Q1 		– Sell
-134,877
Closed -$229K – 1659
2023
Q4 		$229K Buy
+134,877
New +$149K ﹤0.01% 1215
2018
Q4 		– Sell
-183
Closed -$6K – 1764
2018
Q3 		$6K Buy
+183
New +$6.82K ﹤0.01% 1612

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Acadian Asset Management's HRTX Position: Q2 2026 in Review

Acadian Asset Management reduced its Heron Therapeutics (HRTX) stake by 70% in Q2 2026, selling an estimated $289K and leaving 153,011 shares worth $65K. The position accounts for ﹤0.01% of the portfolio, ranked #1828.

Acadian Asset Management first reported a position in HRTX in Q3 2018 and has held it in 6 quarters since. The position peaked at $409K in Q1 2026. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Acadian Asset Management held 153,011 shares of Heron Therapeutics worth $65K as of Q2 2026.
  • Acadian Asset Management sold 360,157 Heron Therapeutics shares in Q2 2026, an estimated $289K.
  • Heron Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1828 holding.
  • Acadian Asset Management first reported a position in Heron Therapeutics in Q3 2018 and has held it in 6 quarters since.
  • Acadian Asset Management's Heron Therapeutics position peaked at $409K in Q1 2026.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.